Lab-supply companies are normally in the business of selling things to scientists, rather than buying. But the new CEO of Sigma-Aldrich, one of the world's largest lab-supply firms, is shopping for new ideas, new partners - and new companies to invest in.
"I didn't think they would be at this stage for decades, let alone within a year."
Gerald Schatten, colleague of Korea's stem-cell celebrity, before scandal broke
European exchanges are opening back up for riskier ventures, and experts expect the trend to continue. But trade-sales should still dominate, says Mary Lisbeth D'Amico.
Sworn enemies within the technology and pharmaceutical industries are joining forces in a lobbying drive to persuade European Union lawmakers to change a draft law they say will stifle innovation in Europe by criminalising patent infringements, along with all forms of intellectual property infringements.
Time and money are driving the world’s pharmaceutical companies east for their clinical trials. With its huge population, new helpful regulations and growth outstripping China, India plans to become the world leader in the clinical research business by the end of the decade.
At any given time over 1.4 million people worldwide are suffering from infections they got from their health-provider, according to the World Health Organization. Pelias AG, a newly created affiliate of Austrian biotech company Intercell AG, is hoping to raise €15 million to €20 million to make a dent in those numbers.
News Editor Thomas Lau spoke to Florian Schönharting, a partner at the Nordic Biotech, a fund that has invested in Denmark’s Gastrotech BipPharma - a biotechnology company that recently merged with US biotech firm DOR BioPharma. Nordic Biotech, a specialised biotech venture capital fund focusing primarily on Nordic countries and the EU, has invested in Gastrotech since its inception in March 2003.
Diamonds are the hardest natural substance known to man, and hard to find too. But Russian scientists say they have found a way to make prospecting for the precious mineral much easier.
Cambridge University is tightening its grip on rights to intellectual property generated by staff and students after academics voted overwhelmingly to endorse new plans
Investing in technology that's a few years from commercialisation can be tricky. Lori Valigra finds out how some venture capitalists sort the wheat from the chaff.
A Swiss team has developed a reliable blood test for younger, live cows. Now it is looking for investment to develop a test for Creutzfeldt-Jakob disease in humans.
With the US in regulatory limbo, Europe is winning the race to be the first regulated drugs market to approve generic copies of biotech drugs - despite the protests of the biotech pioneers who created them.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.